FS Reports最新文献

{"title":"The role of elagolix in ovulation suppression during controlled ovarian stimulation: a retrospective cohort study","authors":"David Soliman M.Sc. ,&nbsp;Rita Naoom B.Sc. ,&nbsp;Mohamed Zaied B.Sc. ,&nbsp;Samuel Soliman M.D.","doi":"10.1016/j.xfre.2024.06.006","DOIUrl":"10.1016/j.xfre.2024.06.006","url":null,"abstract":"<div><h3>Objective</h3><div>To compare in vitro fertilization treatment outcomes for the oral gonadotropin-releasing hormone (GnRH) antagonist elagolix (E) to the conventionally used injectable GnRH antagonist ganirelix (G) for achieving pituitary gonadotropin suppression during a controlled ovarian stimulation (COS) cycle.</div></div><div><h3>Design</h3><div>Retrospective cohort study.</div></div><div><h3>Setting</h3><div>Private university-affiliated fertility center.</div></div><div><h3>Patient(s)</h3><div>One hundred and ninety-four infertility patients receiving either E or G for pituitary suppression during the COS cycle.</div></div><div><h3>Exposure</h3><div>Use of E for ovulation suppression during the COS cycle.</div></div><div><h3>Main Outcome Measure(s)</h3><div>Biochemical pregnancy, sustained implantation, and cycle cancellation rates were the primary outcome measures. Secondary outcomes included miscarriage, fertilization, and blastulation rates.</div></div><div><h3>Result(s)</h3><div>The groups did not differ in their baseline demographic characteristics (age, body mass index, hormone profiles, total dosage of gonadotropins, number of oocytes retrieved, and number of embryos transferred). The overall cycle cancellation rates were 7.0% and 4.9% for e and G, respectively, and the difference was not statistically significant. For the frozen embryo transfers, the biochemical pregnancy, sustained implantation, and miscarriage rates for E were 74.5%, 51.0%, and 31.6%, respectively. For G, these were 55.9%, 39.8%, and 28.8%. Out of these outcomes, only the biochemical pregnancy rates were significantly different. For the fresh embryo transfers, biochemical pregnancy, sustained implantation, and miscarriage rates for E were 33.3%, 33.3%, and 0.0%, and for G, they were 37.5%, 25.0%, and 33.3%. None of the differences reached significance.</div></div><div><h3>Conclusion(s)</h3><div>The oral GnRH antagonist, E, may be as effective as the injected antagonist, G, regarding embryological and clinical outcomes and could offer a less invasive, more cost-effective, and “patient-friendly” approach to pituitary suppression for in vitro fertilization treatment.</div></div>","PeriodicalId":34409,"journal":{"name":"FS Reports","volume":"5 4","pages":"Pages 356-362"},"PeriodicalIF":0.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141700836","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Patterns of utilization of advanced practice providers in reproductive endocrinology: a 2023 national survey","authors":"Tamara Tobias A.R.N.P., W.H.N.P.-B.C. ,&nbsp;Nicole Callahan M.S.N., F.N.P.-C. ,&nbsp;Laura Augustine D.N.P., F.N.P.-C. ,&nbsp;Barbara Tanaka M.S.N., W.H.N.P.-B.C.","doi":"10.1016/j.xfre.2024.09.002","DOIUrl":"10.1016/j.xfre.2024.09.002","url":null,"abstract":"<div><h3>Objective</h3><div>To evaluate the current utilization of advanced practice providers (APPs) within the field of reproductive endocrinology and infertility.</div></div><div><h3>Design</h3><div>Cross-sectional.</div></div><div><h3>Setting</h3><div>Web-based.</div></div><div><h3>Patients</h3><div>A total of 201 APPs surveyed through the American Society of Reproductive Medicine APP Professional Group.</div></div><div><h3>Exposure</h3><div>Anonymized online survey.</div></div><div><h3>Main Outcome Measures</h3><div>Demographics, scope of practice and responsibilities, and training and onboarding.</div></div><div><h3>Results</h3><div>Respondents were primarily Family Nurse Practitioners (26.4%), Women’s Health Nurse Practitioners (33.3%), or Physician Associates (29.8%). Two-thirds (67.4%) reported that their scope of practice is limited by their employer or practice, 43.5% by state restrictions, and 25.2% by insurance. Survey respondents reported that 44.4% of their time at work is dedicated to performing procedures and scans and 30.6% to conducting consults and follow-ups. The most commonly reported duties were physical examinations (88.6%), intrauterine inseminations (86.6%), saline sonohysterograms (79.6%), endometrial biopsies (76.6%), ultrasounds (74.6%), and problem visits such as for pain, cysts, and bleeding (73.1%). Most survey respondents (61.7%) reported having autonomy in deciding protocols and treatment options for patients in their practice. Respondents described their onboarding training as including observation/on-the-job training (94.0%), independent reading of texts and journals (66.7%), American Society of Reproductive Medicine online courses (45.3%), formal orientation (34.8%), and practice-organized training programs (29.4%).</div></div><div><h3>Conclusions</h3><div>Advanced practice providers are highly trained members of the care team, but continue to be underused within the field of reproductive endocrinology and infertility. Improvements in educational resources and/or use of a formalized program to train APPs to their full scope of practice may help increase clinic efficiency and improve patient access to care.</div></div>","PeriodicalId":34409,"journal":{"name":"FS Reports","volume":"5 4","pages":"Pages 363-368"},"PeriodicalIF":0.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11705595/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142955936","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Validation of a mail-in delayed semen analysis protocol developed for home collection","authors":"Karen Racicot Ph.D. ,&nbsp;Denny Sakkas Ph.D. ,&nbsp;Brent C. Barrett Ph.D. ,&nbsp;Kenneth Chiang Ph.D. ,&nbsp;Charles Jenkins B.S.","doi":"10.1016/j.xfre.2024.10.005","DOIUrl":"10.1016/j.xfre.2024.10.005","url":null,"abstract":"<div><h3>Objective</h3><div>To validate a mail-in delayed semen analysis service using deidentified remnant samples from a US fertility clinic.</div></div><div><h3>Design</h3><div>Double-blinded prospective validation of screening/diagnostic test.</div></div><div><h3>Setting</h3><div>Fertility clinic and clinical reference laboratory.</div></div><div><h3>Patient(s)</h3><div>Deidentified remnant samples from patients attending fertility clinic for fertility assessment (study A, n = 68; study B, n = 232).</div></div><div><h3>Intervention(s)</h3><div>None.</div></div><div><h3>Main Outcome Measure(s)</h3><div>Total motility, concentration, and morphology (Kruger, strict) measures were compared between split semen specimens that underwent comprehensive semen analysis at &lt;1 hour (referent) and 26 hours (experimental). The concordance between the paired measures was described using coefficient of variance and percent bias. Clinical concordance (CC) between 1- and 26-hour results for total motility, concentration, and morphology measures was also reported, using the fifth centile clinical reference ranges described in the World Health Organization manual (fifth edition).</div></div><div><h3>Result(s)</h3><div>In a controlled laboratory setting (study A), total motility, concentration, and morphology measures were highly consistent between the 1- and 26-hour analyses, with mean coefficients of variation (%CVs) of 9.0% for total motility, 4.0% for concentration, and 3.0% for morphology. There were also high CC rates: 94.2% for total motility; 100% for concentration; and 98.5% for morphology. In a real-world setting (study B), which included commercial shipment of specimens, the mean %CVs for total motility and concentration were 15% and 27%, respectively, which were more variable than those in study A yet still considerably less variable than that measured between laboratories using College of Anatomical Pathologist proficiency testing during the study period (motility %CV, 31%; concentration %CV, 37%). These comparisons also had high CC rates for total motility (86%) and concentration (93.1%).</div></div><div><h3>Conclusion(s)</h3><div>These results demonstrate the validation of a laboratory service that provides accurate, comprehensive semen analysis on specimens collected remotely and shipped overnight to a clinical diagnostic laboratory.</div></div>","PeriodicalId":34409,"journal":{"name":"FS Reports","volume":"5 4","pages":"Pages 378-384"},"PeriodicalIF":0.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11705597/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142956052","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Disparities in infertility workup costs across the United States","authors":"Naveena R. Daram M.D. ,&nbsp;Malika L. Day M.S. ,&nbsp;Rose A. Maxwell Ph.D. ,&nbsp;Meghan C. Ozcan M.D.","doi":"10.1016/j.xfre.2024.09.005","DOIUrl":"10.1016/j.xfre.2024.09.005","url":null,"abstract":"<div><h3>Objective</h3><div>To investigate cost disparities of infertility diagnostic tests across the United States.</div></div><div><h3>Design</h3><div>Cross-sectional study analyzing costs for recommended infertility diagnostic tests, including hormone tests (follicle stimulating hormone, luteinizing hormone, estradiol, and progesterone), semen analysis, transvaginal ultrasound, and hysterosalpingogram. Data were sourced from consumer cost claims repositories for five most populous cities per state, categorized into four regions (Midwest, South, West, and Northeast) as per US Census Bureau classifications. Descriptive statistics and analysis of variance with Tukey’s post hoc tests evaluated cost variations across states and regions.</div></div><div><h3>Setting</h3><div>Not applicable.</div></div><div><h3>Patient(s)</h3><div>No individual subject data.</div></div><div><h3>Exposure</h3><div>Not applicable.</div></div><div><h3>Main Outcome Measure(s)</h3><div>Average costs for infertility diagnostic tests by states/regions, correlated with median household income, race, poverty, uninsured rate, and insurance mandates.</div></div><div><h3>Result(s)</h3><div>Alaska had highest total cost at $2,986, with Oregon the lowest at $835. Costs for all tests, except follicle stimulating hormone, varied significantly across states. Regional variations were noted, with luteinizing hormone, estradiol, transvaginal ultrasound, and hysterosalpingogram showing significant differences. Total workup costs varied by region, with Midwest having the highest average at $1,651, positively correlated with median household income, followed by Northeast, West, and South. States with insurance mandates for fertility coverage had lower uninsured rates. No correlation was found between state insurance mandates and costs.</div></div><div><h3>Conclusion(s)</h3><div>The study highlights significant regional cost disparities in infertility care, emphasizing complexities of access and affordability in the United States. Further research is needed to assess the out-of-pocket financial burden on patients and identify strategies to reduce these costs.</div></div>","PeriodicalId":34409,"journal":{"name":"FS Reports","volume":"5 4","pages":"Pages 422-429"},"PeriodicalIF":0.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11705584/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142956079","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Elagolix for ovulation suppression in in vitro fertilization: Is it time to switch from the painful costly injectables?","authors":"Zaher Merhi M.D., H.C.L.D.","doi":"10.1016/j.xfre.2024.11.001","DOIUrl":"10.1016/j.xfre.2024.11.001","url":null,"abstract":"","PeriodicalId":34409,"journal":{"name":"FS Reports","volume":"5 4","pages":"Pages 350-351"},"PeriodicalIF":0.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11705568/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142956081","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Personalized medicine in the evaluation of Müllerian anomalies: the role of three-dimensional printing technology","authors":"","doi":"10.1016/j.xfre.2024.05.003","DOIUrl":"10.1016/j.xfre.2024.05.003","url":null,"abstract":"<div><h3>Objective</h3><p>To present the comprehensive methodology for generating personalized three-dimensional (3D) printed uterine models from 3D ultrasound (US) volumes in individuals diagnosed with Müllerian anomalies and discuss potential applications in the field of reproductive endocrinology and infertility.</p></div><div><h3>Design</h3><p>Pilot study.</p></div><div><h3>Setting</h3><p>Single large university-affiliated teaching hospital.</p></div><div><h3>Patient(s)</h3><p>Patients with the presence of a Müllerian anomaly between the ages of 18 and 45 years attending the maternal-fetal medicine as well as reproductive endocrinology and infertility outpatient offices from 2018 to 2023 were included in the study.</p></div><div><h3>Intervention(s)</h3><p>Subjects underwent 3D US transvaginal scanning for the collection of data. The 3D US volumes were acquired, edited, and exported from a US cart Voluson E10 system (GE Healthcare, Chicago, IL). High-definition virtual models were created and modified, making them suitable for printing using Materialise 3-Matic Medical (Materialise NV, Leuven, Belgium). The models were printed on a J5 MediJet 3D printer (Stratasys, Rehovot, Israel). Colors were set to mimic a realistic appearance, and shore values were set before printing.</p></div><div><h3>Main Outcome Measure(s)</h3><p>Successful creation and utilization of personalized 3D-printed uterine models for individuals with Müllerian anomalies.</p></div><div><h3>Results(s)</h3><p>Three-dimensional models were created for a uterus without anomalies, 2 variations of a partial septum, a unicornuate, and a didelphys uterus. Models were used as a tactile and customized tool for patient education, counseling, and medical student and resident teaching. This technique illustrates that the creation of personalized 3D-printed uterine models for utilization in the fields of reproductive endocrinology and infertility is feasible.</p></div><div><h3>Conclusion(s)</h3><p>We propose a novel use of individualized 3D-printed uterine models in the evaluation of individuals with Müllerian anomalies. These models may play a complementary role to standard imaging options in the assessment of these anomalies, with a special potential for application in highly complex or yet-to-be-determined types of anomalies.</p></div>","PeriodicalId":34409,"journal":{"name":"FS Reports","volume":"5 3","pages":"Pages 279-284"},"PeriodicalIF":0.0,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2666334124000540/pdfft?md5=5af7ade16b3d1ced3d5c0a018a164e52&pid=1-s2.0-S2666334124000540-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141057838","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Assisted same-sex conception: reproduction reimagined","authors":"","doi":"10.1016/j.xfre.2024.02.011","DOIUrl":"10.1016/j.xfre.2024.02.011","url":null,"abstract":"","PeriodicalId":34409,"journal":{"name":"FS Reports","volume":"5 3","pages":"Pages 234-236"},"PeriodicalIF":0.0,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2666334124000400/pdfft?md5=fe79ac56a5e5edf90a0117e459f87701&pid=1-s2.0-S2666334124000400-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140463953","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Progesterone in frozen embryo transfer cycles: assays, circulating concentrations, metabolites, and molecular action","authors":"","doi":"10.1016/j.xfre.2024.05.007","DOIUrl":"10.1016/j.xfre.2024.05.007","url":null,"abstract":"<div><p>Programmed or medicated frozen embryo transfer cycles rely on exogenous progesterone (P) administration to prepare the endometrium for implantation and maintain pregnancy. Presently, the optimal route and dose of P replacement for frozen embryo transfer are not known. In addition, there is a paucity of data and insufficient understanding regarding the metabolism and actions of P in implantation and pregnancy maintenance. In the present review, we discuss how different P assay methodologies affect the determination of P thresholds for implantation and pregnancy maintenance. In addition, we discuss the importance of free P and its regulation in the endometrium and show the complexity of molecular signaling that is required for P-dependent endometrial receptivity. We concluded that future studies should focus on defining accurate circulating and endometrial P concentrations, both for total and free P, and how these concentrations correlate with endometrial receptivity and clinical outcomes.</p></div>","PeriodicalId":34409,"journal":{"name":"FS Reports","volume":"5 3","pages":"Pages 237-247"},"PeriodicalIF":0.0,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2666334124000588/pdfft?md5=1ccf5f84b5dd14e381c28f2913e461e7&pid=1-s2.0-S2666334124000588-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141136929","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Hepatitis B virus in oocytes and embryos: pregnancy outcomes and children’s health","authors":"Xiaoling Hu Ph.D. ,&nbsp;Yingzhi Yang M.D. ,&nbsp;Guofang Feng M.D. ,&nbsp;Xiaoqian Zhou M.D. ,&nbsp;Minyue Tang Ph.D. ,&nbsp;Huanmiao Yan M.D. ,&nbsp;Miao Li M.D. ,&nbsp;Aixia Liu Ph.D. ,&nbsp;Yimin Zhu Ph.D.","doi":"10.1016/j.xfre.2024.07.002","DOIUrl":"10.1016/j.xfre.2024.07.002","url":null,"abstract":"<div><h3>Objective</h3><p>To investigate whether the presence of hepatitis B virus (HBV) in oocytes and embryos affects pregnancy outcomes for in vitro fertilization and embryo transfer (ET) as well as is related to the vertical transmission of HBV to children.</p></div><div><h3>Design</h3><p>Retrospective cohort study.</p></div><div><h3>Setting</h3><p>A university-affiliated fertility center.</p></div><div><h3>Patient(s)</h3><p>This study included 167 couples with at least 1 hepatitis B surface antigen–seropositive partner. These couples underwent in vitro fertilization–ET, and the discarded oocytes and embryos had been tested for HBV. Couples with HBV-positive oocytes or embryos were categorized as the positive group, whereas those couples with HBV-negative oocytes and embryos served as the negative group.</p></div><div><h3>Intervention(s)</h3><p>None.</p></div><div><h3>Main Outcome Measure(s)</h3><p>Pregnancy outcomes and the rate of children’s HBV infection.</p></div><div><h3>Result(s)</h3><p>The pregnancy outcomes of fresh and frozen ETs were not associated with the presence of HBV in the oocytes and embryos. Of the 106 infants born, 1 child whose mother tested positive for hepatitis B surface antigen but had negative oocytes and embryos was infected with HBV. Additionally, 26.09% of children who had been administered passive immunization and active vaccinations did not reach protective levels of anti-HBV antibodies (hepatitis B surface antibodies) and became nonresponders. The negative rate of children’s hepatitis B surface antibody was associated with the presence of HBV in oocytes and embryos (odds ratio, 3.01; 95% confidence interval, 1.04–9.25).</p></div><div><h3>Conclusion(s)</h3><p>The presence of HBV in oocytes and embryos did not affect pregnancy outcomes or result in the vertical transmission of HBV to the offspring of HBV carriers. Follow-up is needed for HBV-vaccinated children with an HBV-infected parent. Booster vaccinations are necessary for continued protection.</p></div>","PeriodicalId":34409,"journal":{"name":"FS Reports","volume":"5 3","pages":"Pages 272-278"},"PeriodicalIF":0.0,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2666334124000795/pdfft?md5=5534de5c5012e8a0ec65524f9ad0ef92&pid=1-s2.0-S2666334124000795-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141690047","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The geographic impact on successfully matching into reproductive endocrinology and infertility fellowship","authors":"Megan R. Sax M.D.","doi":"10.1016/j.xfre.2024.08.003","DOIUrl":"10.1016/j.xfre.2024.08.003","url":null,"abstract":"","PeriodicalId":34409,"journal":{"name":"FS Reports","volume":"5 3","pages":"Page 251"},"PeriodicalIF":0.0,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2666334124000849/pdfft?md5=094e9ca0471394ad047000ade85b1589&pid=1-s2.0-S2666334124000849-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142240900","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}